Cargando…

Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer

Purpose. To assess the prognostic role of 14F7 Mab immunoreactivity, against N-Glycolyl GM3 ganglioside, in patients with colon cancer (CC) and to evaluate the relationship between its expression and clinicopathological features. Methods. Paraffin-embedded specimens were retrospectively collected fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lahera, Tania, Calvo, Adanays, Torres, Griselda, Rengifo, Charles E., Quintero, Santiago, Arango, María del Carmen, Danta, Debora, Vázquez, José M., Escobar, Xiomara, Carr, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930184/
https://www.ncbi.nlm.nih.gov/pubmed/24639871
http://dx.doi.org/10.1155/2014/482301
_version_ 1782304506849001472
author Lahera, Tania
Calvo, Adanays
Torres, Griselda
Rengifo, Charles E.
Quintero, Santiago
Arango, María del Carmen
Danta, Debora
Vázquez, José M.
Escobar, Xiomara
Carr, Adriana
author_facet Lahera, Tania
Calvo, Adanays
Torres, Griselda
Rengifo, Charles E.
Quintero, Santiago
Arango, María del Carmen
Danta, Debora
Vázquez, José M.
Escobar, Xiomara
Carr, Adriana
author_sort Lahera, Tania
collection PubMed
description Purpose. To assess the prognostic role of 14F7 Mab immunoreactivity, against N-Glycolyl GM3 ganglioside, in patients with colon cancer (CC) and to evaluate the relationship between its expression and clinicopathological features. Methods. Paraffin-embedded specimens were retrospectively collected from 50 patients with CC operated between 2004 and 2008. 14F7 Mab staining was determined by immunohistochemistry technique and its relation with survival and clinicopathologic features was evaluated. Results. The reactivity of 14F7 Mab was detected in all cases. Most cases had high level of immunostaining (70%) that showed statistical correlation with TNM stage (P = 0.025). In univariate survival analysis, level of 14F7 Mab immunoreactivity (P = 0.0078), TNM Stage (P = 0.0007) and lymphovascular invasion (0.027) were significant prognostic factors for overall survival. Among these variables, level of 14F7 Mab immunoreactivity (HR = 0.268; 95% CI  0.078–0.920; P = 0.036) and TNM stage (HR = 0.249; 95% CI 0.066–0.932; P = 0.039) were independent prognostic factors on multivariate analysis. Conclusions. This study is the first approach on the prognostic significance of 14F7 Mab immunoreactivity in patients with colon adenocarcinoma and this assessment might be used in the prognostic estimate of CC, although further studies will be required to validate these findings.
format Online
Article
Text
id pubmed-3930184
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39301842014-03-17 Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer Lahera, Tania Calvo, Adanays Torres, Griselda Rengifo, Charles E. Quintero, Santiago Arango, María del Carmen Danta, Debora Vázquez, José M. Escobar, Xiomara Carr, Adriana J Oncol Research Article Purpose. To assess the prognostic role of 14F7 Mab immunoreactivity, against N-Glycolyl GM3 ganglioside, in patients with colon cancer (CC) and to evaluate the relationship between its expression and clinicopathological features. Methods. Paraffin-embedded specimens were retrospectively collected from 50 patients with CC operated between 2004 and 2008. 14F7 Mab staining was determined by immunohistochemistry technique and its relation with survival and clinicopathologic features was evaluated. Results. The reactivity of 14F7 Mab was detected in all cases. Most cases had high level of immunostaining (70%) that showed statistical correlation with TNM stage (P = 0.025). In univariate survival analysis, level of 14F7 Mab immunoreactivity (P = 0.0078), TNM Stage (P = 0.0007) and lymphovascular invasion (0.027) were significant prognostic factors for overall survival. Among these variables, level of 14F7 Mab immunoreactivity (HR = 0.268; 95% CI  0.078–0.920; P = 0.036) and TNM stage (HR = 0.249; 95% CI 0.066–0.932; P = 0.039) were independent prognostic factors on multivariate analysis. Conclusions. This study is the first approach on the prognostic significance of 14F7 Mab immunoreactivity in patients with colon adenocarcinoma and this assessment might be used in the prognostic estimate of CC, although further studies will be required to validate these findings. Hindawi Publishing Corporation 2014 2014-01-30 /pmc/articles/PMC3930184/ /pubmed/24639871 http://dx.doi.org/10.1155/2014/482301 Text en Copyright © 2014 Tania Lahera et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lahera, Tania
Calvo, Adanays
Torres, Griselda
Rengifo, Charles E.
Quintero, Santiago
Arango, María del Carmen
Danta, Debora
Vázquez, José M.
Escobar, Xiomara
Carr, Adriana
Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
title Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
title_full Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
title_fullStr Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
title_full_unstemmed Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
title_short Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer
title_sort prognostic role of 14f7 mab immunoreactivity against n-glycolyl gm3 ganglioside in colon cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930184/
https://www.ncbi.nlm.nih.gov/pubmed/24639871
http://dx.doi.org/10.1155/2014/482301
work_keys_str_mv AT laheratania prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT calvoadanays prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT torresgriselda prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT rengifocharlese prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT quinterosantiago prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT arangomariadelcarmen prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT dantadebora prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT vazquezjosem prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT escobarxiomara prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer
AT carradriana prognosticroleof14f7mabimmunoreactivityagainstnglycolylgm3gangliosideincoloncancer